Wellsaaen3039
Glucose is an important material in human metabolism. The establishment of glucose reference measurement procedures and to study the uncertainties of measurement is of great significance. Linear fitting and dilution of reference material were used in the measurement of glucose concentration and they are common operations in daily work. Investigation of the measurement uncertainty of these operations will be of important significance to clinical laboratory medicine. However, in the field of laboratory medicine, related research was rarely reported.
The spectrometric quantification of glucose is an application of the enzymatic reference method with hexokinase. The sources of uncertainty in the measurement process were analyzed. The measurement uncertainties in the study were evaluated according to GUF method and the method introduced by Quantifying Uncertainty in Analytical Measurement (QUAM) was also applied in the evaluation of the measurement of linear fitting.
The standard curve was built successfully according to the measurement procedure recommended by the CDC and the linear equation was y = 0.000807x + 0.001213 (R2 = 0.999179). The measurement uncertainty of glucose in the sample was 0.450,408 mmol/L.
The method for the determination of serum glucose concentration by hexokinase in our laboratory has been successfully established. The measurement uncertainty was consistent with the GUF method and the method introduced by Quantifying Uncertainty in Analytical Measurement (QUAM) in the process of linear fitting when the glucose concentration was measured by the reference method (hexokinase method).
The method for the determination of serum glucose concentration by hexokinase in our laboratory has been successfully established. The measurement uncertainty was consistent with the GUF method and the method introduced by Quantifying Uncertainty in Analytical Measurement (QUAM) in the process of linear fitting when the glucose concentration was measured by the reference method (hexokinase method).
PD-L1 expression on tumor-infiltrating lymphocytes (TILs) has recently been reported as a biomarker for colorectal cancer (CRC). However, the prognostic and clinical significance of PD-L1 on TILs in CRC remains controversial. We performed this meta-analysis to evaluate the association between the PD-L1 expression on TILs and clinicopathological features and prognosis of CRC patients.
A comprehensive literature search for relevant studies published up to Feb 2020 was performed using Medline, Embase, and Web of Science. Odds ratio (OR) with 95% CI was selected to appraise the correlation between PD-L1 expression on TILs with prognostic and clinicopathological characteristics of CRC patients. Begg's and Egger's test were used to assess publication bias. The statistical analysis was conducted using Stata software.
A total of 19 studies including 5,213 CRC cases were included in this meta-analysis. The pooled results showed that PD-L1 overexpression on TILs was relevant to longer OS (OR = 1.36, 95% CI = 1.19t.
This meta-analysis revealed that PD-L1 expression on TILs can serve as a significant biomarker for positive prognosis and clinicopathological features of CRC. Our results may provide some useful information when using PD-L1 expression to predict the survival of CRC patients and to select the beneficial CRC patients from PD-1/PD-L1 antibody treatment.
To explore the associations of changes in serum inflammatory factors, matrix metalloproteinase-3 (MMP-3), 25-hydroxy vitamin D [25(OH)D], and intestinal flora with osteoporosis and disease activity in rheumatoid arthritis (RA) patients, so as to provide references for clinical diagnosis and treatment.
A total of 98 RA patients were selected as the objects of study (RA group), and divided into active-stage group (n = 56) and remission-stage group (n = 42) according to the disease activity score (DAS28). Another 50 healthy people receiving physical examination in our hospital during the same period were selected as the control group. The changes in serum inflammatory factors, MMP-3, 25(OH)D, and intestinal flora were compared among the three groups, and the osteoporosis of the subjects was analyzed in each group. selleck inhibitor Moreover, the associations of changes in serum inflammatory factors, MMP-3, 25(OH)D, and intestinal flora with osteoporosis and disease activity in RA patients were analyzed using the Pearson's metnd in-testinal flora with osteoporosis and disease activity in RA patients, showing certain value in clinical application.
Congenital alpha-2 antiplasmin deficiency is a rare, often misdiagnosed coagulopathy that may result in severe hemorrhage. Homozygous patients develop symptomatology in early childhood, while heterozygous individuals may be asymptomatic or bleed profusely following invasive dental procedures, surgery or trauma late in life. Due to the rarity of this entity, we performed an analysis of reported cases of congenital alpha-2 antiplasmin deficiency to share uncommon cases with the medical community, to raise awareness of the condition among clinicians, and to promote better patient management.
To identify relevant studies, PubMed and Science Direct were searched using controlled vocabulary and keywords based on medical subject headings (MeSH). Data of all reported cases of congenital alpha-2 antiplasmin deficiency were extracted and summarized for study setting, patient characteristics, and types of treatments.
Thirty-three publications were identified encompassing one hundred twenty-three patients. This manuscript presents many important clinical conditions that are uncommon and may go undetected by medical personnel. It illustrates the importance of considering alpha-2 antiplasmin deficiency in the work-up of patients who present with a severe bleeding phenotype and may have normal coagulation screening tests. Management of such patients may be challenging especially when the diagnosis of alpha-2 antiplasmin deficiency is not known.
Improved awareness and access to diagnostic tools will contribute to better management of rare co-agulopathies.
Improved awareness and access to diagnostic tools will contribute to better management of rare co-agulopathies.